Background Immune checkpoint inhibitors (ICI) have demonstrated impressive activity in
metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment …

Abstract Background Immune checkpoint inhibitors (ICIs) are being increasingly utilised in
the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited …

The prognosis for advanced clear cell renal cell carcinoma (ccRCC) is not satisfactory, even
though its treatment has evolved rapidly over the past 20 years. Systemic ccRCC treatment …

Background: Immune checkpoint inhibitors (ICIs) are effective for advanced renal-cell
carcinoma (aRCC) but can increase costs. This study compares the efficacy, safety and cost …

Simple Summary Renal cancer is within the top 10 most common malignancies worldwide,
of which clear cell histology represents the most common subtype in this cancer. Within the …

Simple Summary Kidney cancer has many forms, which fall under the overall term, renal cell
carcinoma. Clear cell renal cell carcinoma is by far the most common type, and all other …

Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell
carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and …

Simple Summary We evaluated the efficacy and safety of immune checkpoint inhibitors
(ICIs) and tyrosine kinase inhibitors (TKI)(ICI+ TKI) in 51 patients with advanced or …

The recent randomized controlled phase III CLEAR trial results are the last to complement
immune checkpoint inhibitor (ICI)-based doublet combination therapies for treatment-naïve …

The category of non-clear cell renal cell carcinoma (nccRCC) includes several clinically,
histologically, and molecularly diverse entities. Traditionally, they comprise type 1 and type 2 …